Difference between revisions of "Rituximab-abbs (Truxima)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
m (→Also known as) |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| − | *[[Acquired | + | *[[Acquired hemophilia A]] |
*[[Immune thrombocytopenia (ITP)]] | *[[Immune thrombocytopenia (ITP)]] | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| Line 36: | Line 36: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert] | *[http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert] | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, [[:Category:Indolent_lymphomas|low grade]] or [[Follicular lymphoma|follicular]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]] B-cell NHL as a single agent. | *2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, [[:Category:Indolent_lymphomas|low grade]] or [[Follicular lymphoma|follicular]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]] B-cell NHL as a single agent. | ||
| − | *2018-11-28: Initial approval for the treatment of adult patients with previously untreated [[Follicular lymphoma|follicular]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]], B-cell NHL in combination with first line chemotherapy | + | *2018-11-28: Initial approval for the treatment of adult patients with previously untreated [[Follicular lymphoma|follicular]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]], B-cell NHL in combination with first line chemotherapy. |
| + | *2018-11-28: Initial approval as single-agent maintenance therapy for the treatment of adult patients with [[Follicular lymphoma|follicular]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]], B-cell NHL achieving a complete or partial response to a rituximab product in combination with chemotherapy. | ||
*2018-11-28: Initial approval for the treatment of adult patients with non-progressing (including stable disease), [[:Category:Indolent_lymphomas|low-grade]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]], B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. | *2018-11-28: Initial approval for the treatment of adult patients with non-progressing (including stable disease), [[:Category:Indolent_lymphomas|low-grade]], [[Biomarkers#CD20|CD20]]-[[Biomarkers#Expression|positive]], B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. | ||
==Also known as== | ==Also known as== | ||
| − | *'''Brand | + | *'''Code name:''' CT-P10 |
| + | *'''Brand name:''' Truxima | ||
==References== | ==References== | ||
| Line 56: | Line 58: | ||
[[Category:Anti-CD20 antibodies]] | [[Category:Anti-CD20 antibodies]] | ||
| − | [[Category:Acquired | + | [[Category:Acquired hemophilia A medications]] |
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
Latest revision as of 13:13, 26 May 2024
Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.
General information
Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Acquired hemophilia A
- Immune thrombocytopenia (ITP)
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Castleman disease
- Chronic lymphocytic leukemia
- CNS lymphoma
- Cold agglutinin disease
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hairy cell leukemia
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Inherited coagulopathy with inhibitor
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Acquired thrombotic thrombocytopenic purpura
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Rituximab (Rituxan) package insert
- Rituximab (Rituxan) patient drug information (Chemocare)[1]
- Rituximab (Rituxan) patient drug information (UpToDate)[2]
History of changes in FDA indication
- 2018-11-28: Initial approval for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
- 2018-11-28: Initial approval for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy.
- 2018-11-28: Initial approval as single-agent maintenance therapy for the treatment of adult patients with follicular, CD20-positive, B-cell NHL achieving a complete or partial response to a rituximab product in combination with chemotherapy.
- 2018-11-28: Initial approval for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
Also known as
- Code name: CT-P10
- Brand name: Truxima
References
Categories:
- Drugs
- Intravenous medications
- Neutral
- Protein expression-specific medications
- Anti-CD20 antibodies
- Acquired hemophilia A medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Castleman disease medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia medications
- Cold agglutinin disease medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Hairy cell leukemia medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenia medications
- Inherited coagulopathy medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Acquired thrombotic thrombocytopenic purpura medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 2018
- Biosimilars
- WHO Essential Cancer Medicine